Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
Search results for: biosimilars
FDA Grants Interchangeable Designation to Pfizer’s Abrilada, Biosimilar to AbbVie’s Humira
On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Marching to the Biosimilar Beat: Questions on Rollout Remain
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Expert Guidance from the ACR/ARP Access in Rheumatology Meeting
ACR/ARP Access in Rheumatology—As part of ACR Education Exchange 2023, the ACR/ARP Access in Rheumatology meeting addressed some of the major challenges in coverage and payment that U.S. rheumatology practices face. Speakers included rheumatologists, rheumatology professionals, office managers and CEOs. The first section, Thriving, Not Just Surviving—Keeping Your Rheumatology Practice Solvent, focused on financial management…
Expert Guidance from the ACR/ARP Access in Rheumatology Meeting
Speakers addressed major challenges in coverage and payment facing rheumatology practices, including financial management and obstacles to patient access to treatment.
Rheumatology Priorities Advanced at Busy AMA House of Delegates Meeting
Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.
ACR to Lead Resolutions at June AMA House of Delegates Meeting
The ACR will co-lead with the American Society of Clinical Oncology a resolution on in-office dispensing of specialty drugs and will lead 10 other specialty societies to advance a resolution on the proposed NIH Public Access Plan and equitable access to quality clinical research.
Psoriatic Arthritis Drugs at a Glance, 2023
Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…
The ACR Takes a Stand: How Position Statements Are Created
Through the development of position statements that lay out the ACR’s official stance on issues related to the management of rheumatic and musculoskeletal conditions, the Committee on Rheumatologic Care helps outline policies that affect the practice of rheumatology and the wellbeing and care of patients.
First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles
After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 28
- Next Page »